Inventor · disambiguated record
Mustafa Diken
Also filed as: DIKEN MUSTAFA
17 granted patents·12 pending applications·117 citations·filing 2012–2024
92Inventor score
Files withBioNTech SE15BIONTECH RNA PHARMACEUTICALS GMBH9BIONTECH AG1SAHIN UGUR1TRON TRANSLATIONALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ AD1
Top patents by PatentIndex Score
29 records- 0194US10738355B2Individualized vaccines for cancerSAHIN UGUR·Filed 2012·Granted Aug 11, 2020·41 cites·25 claims
- 0293US10717982B2Stabilization of poly(A) sequence encoding DNA sequencesBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2015·Granted Jul 21, 2020·18 cites·19 claims
- 0391US11248264B2Individualized vaccines for cancerTRON TRANSLATIONALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GGMBH·Filed 2020·Granted Feb 15, 2022·5 cites·19 claims
- 0491US10576146B2Particles comprising a shell with RNABIONTECH RNA PHARMACEUTICALS GMBH·Filed 2018·Granted Mar 3, 2020·13 cites·15 claims
- 0589US11559587B2RNA formulation for immunotherapyBioNTech SE·Filed 2019·Granted Jan 24, 2023·3 cites·44 claims
- 0689US10485884B2RNA formulation for immunotherapyBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2013·Granted Nov 26, 2019·16 cites·39 claims
- 0787US11045418B2Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cellBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted Jun 29, 2021·3 cites·8 claims
- 0887US10669322B2RNA molecules encoding cytokine fusion proteins and methods of use thereofBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted Jun 2, 2020·4 cites·28 claims
- 0987US9950065B2Particles comprising a shell with RNABIONTECH AG·Filed 2013·Granted Apr 24, 2018·12 cites·20 claims
- 1080US2025011797A1Stabilization of poly(a) sequence encoding dna sequencesBioNTech SE·Filed 2024·Application pending·0 cites
- 1178US11471522B2Methods and compositions for stimulating immune responseBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2018·Granted Oct 18, 2022·1 cites·30 claims
- 1277US11318195B2Formulation for administration of RNABIONTECH RNA PHARMACEUTICALS GMBH·Filed 2017·Granted May 3, 2022·1 cites·39 claims
- 1373US11337922B2Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cellBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2021·Granted May 24, 2022·0 cites·17 claims
- 1473US2022282322A1Individualized vaccines for cancerTRON TRANSLATIONALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GG·Filed 2022·Application pending·0 cites
- 1572US2023226217A1Rna formulation for immunotherapyTRON TRANSLATIONALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ AD·Filed 2022·Application pending·0 cites
- 1671US2025213599A1Formulation for administration of rnaBioNTech SE·Filed 2024·Application pending·0 cites
- 1770US12168051B2Methods and compositions for stimulating immune responseBioNTech SE·Filed 2022·Granted Dec 17, 2024·0 cites·24 claims
- 1870US2022249372A1Lipid Particle Formulations for Delivery of RNA and Water-Soluble Therapeutically Effective Compounds to a Target CellBioNTech SE·Filed 2022·Application pending·0 cites
- 1968US2023330198A1Rna for treatment of autoimmune diseasesBioNTech SE·Filed 2023·Application pending·0 cites
- 2066US12054723B2Stabilization of poly(A) sequence encoding DNA sequencesBioNTech SE·Filed 2020·Granted Aug 6, 2024·0 cites·16 claims
- 2165US11660338B2Particles comprising a shell with RNABioNTech SE·Filed 2020·Granted May 30, 2023·0 cites·27 claims
- 2263US12150947B2Formulation for administration of RNABioNTech SE·Filed 2019·Granted Nov 26, 2024·0 cites·16 claims
- 2363US2022313811A1Formulation for administration of rnaBioNTech SE·Filed 2022·Application pending·0 cites
- 2460US2025295744A1Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonistsBioNTech SE·Filed 2022·Application pending·0 cites
- 2557US11701413B2RNA for treatment of autoimmune diseasesBioNTech SE·Filed 2018·Granted Jul 18, 2023·0 cites·8 claims
- 2654US2023145774A1Treatment involving non-immunogenic rna for antigen vaccinationBioNTech SE·Filed 2021·Application pending·0 cites
- 2750US2022378876A1Treatment Involving Therapeutic Antibody and Interleukin-2 (IL2)BioNTech SE·Filed 2020·Application pending·0 cites
- 2847US2022143144A1Treatment involving interleukin-2 (il2) and interferon (ifn)BioNTech SE·Filed 2020·Application pending·0 cites
- 2945US2021113606A1Treatment using cytokine encoding rnaBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mustafa Diken files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →